Abstract: Disclosed are a novel, simple and low-cost method for preparing sitagliptin, as DPP-IV (dipeptidyl peptidase IV) inhibitor, which is useful in treating type 2 diabetes mellitus and key intermediates used in said preparation of sitagliptin.
Type:
Application
Filed:
October 19, 2010
Publication date:
August 23, 2012
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Nam Du Kim, Ji Yeon Chang, Dong Jun Kim, Hyun Seung Lee, Jae Hyuk Jung, Young Kil Chang, Gwan Sun Lee
Abstract: Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.
Type:
Grant
Filed:
October 29, 2008
Date of Patent:
August 14, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Sang Min Yun, Young Ho Moon, Young-Kil Chang, Dong Jin Hong, Ji-Yeon Chang, Moon Sub Lee, Jaeho Yoo, Ji Sook Kim, Cheol Kyung Kim
Abstract: Disclosed are a novel, high-yield method for preparing entecavir and intermediates used therein.
Type:
Application
Filed:
September 15, 2010
Publication date:
August 9, 2012
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Jae Heon Lee, Gha Seung Park, Jin Hee Kim, Tae Jin Choi, Ji Eun Lee, Jung Hee Han, Hyo Jeong Bang, Sun Young Jung, Young Kil Chang, Gwan Sun Lee, Maeng Sup Kim
Abstract: The present invention relates to a method for preparing montelukast, an inhibitor against leukotrienes, and an intermediate used therein. According to the inventive method, high-purity montelukast or its sodium salt can be prepared in a high yield.
Type:
Grant
Filed:
December 11, 2007
Date of Patent:
July 10, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Gwan Sun Lee, Young-Kil Chang, Jaeheon Lee, Chul Hyun Park, Eun-Ju Park, Jaeho Yoo
Abstract: The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient.
Type:
Grant
Filed:
June 5, 2008
Date of Patent:
May 29, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Kwang-Ok Lee, Mi Young Cha, Mi Ra Kim, Young Hee Jung, Chang Gon Lee, Se Young Kim, Keukchan Bang, Bum Woo Park, Bo Im Choi, Yun Jung Chae, Mi Young Ko, Han Kyong Kim, Young-Gil Ahn, Maeng Sup Kim, Gwan Sun Lee
Abstract: A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.
Type:
Grant
Filed:
October 22, 2009
Date of Patent:
April 24, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Young-Min Kim, Dae-Jin Kim, Sung-Min Bae, Chang-Ki Lim, Se-Chang Kwon, Gwan-Sun Lee
Abstract: Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses.
Type:
Grant
Filed:
April 28, 2005
Date of Patent:
February 28, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Young Min Kim, Sung Min Bae, Dae Jin Kim, Dae Hae Song, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
Abstract: Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.
Type:
Grant
Filed:
April 14, 2010
Date of Patent:
February 7, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Young Min Kim, Dae Hae Song, Sung Youb Jung, Chang Hwan Kim, In Young Choi, Se Chang Kwon, Gwan Sun Lee
Abstract: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
Type:
Grant
Filed:
April 17, 2009
Date of Patent:
January 31, 2012
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Tae Hee Ha, Hee Sook Oh, Won Jeoung Kim, Chang Hee Park, Eun Young Kim, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee
Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.
Type:
Application
Filed:
March 18, 2010
Publication date:
January 5, 2012
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.
Type:
Application
Filed:
December 28, 2009
Publication date:
October 13, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Jong Soo Woo, Jae Hyun Park, Yong II Kim, Kyeong Soo Kim, Ho Taek Yim, Ji Hyun Im
Abstract: The present invention relates to a novel, high-yield and low-cost method for preparing entecavir, [1-S-(1?,3?,4?)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, an antiviral agent, and novel intermediates used therein.
Type:
Application
Filed:
December 24, 2009
Publication date:
October 13, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Jaeheon Lee, Gha-Seung Park, Jin Hee Kim, Ji Eun Lee, Chul Hyun Park, Tae Jin Choi, Eun-Ju Park, Cheol Kyung Kim, Eun Jung Lim, Young-Kil Chang, Gwan Sun Lee
Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.
Type:
Application
Filed:
June 5, 2009
Publication date:
October 6, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Jae Hyun Park, Kyeong Soo Kim, Ho Taek Yim, Ji Hyun Im
Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.
Type:
Application
Filed:
February 13, 2009
Publication date:
October 6, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Jae Hyun Park, Kyeong Soo Kim, Ho Taek Yim
Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
Type:
Application
Filed:
April 15, 2011
Publication date:
October 6, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Sung Youb JUNG, Jin Sun KIM, Young Jin PARK, Ki-Doo CHOI, Se Chang KWON, Gwan Sun LEE
Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
Type:
Grant
Filed:
November 13, 2004
Date of Patent:
October 4, 2011
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Sung Youb Jung, Jin Sun Kim, Young Jin Park, Ki-Doo Choi, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.
Type:
Grant
Filed:
December 20, 2005
Date of Patent:
August 23, 2011
Assignee:
Hanmi Holdings Co., Ltd.
Inventors:
Young Jin Ham, Ji Hyeon Gong, Mi Young Cha, Jong Woo Kim, Maeng Sup Kim, Eun Young Kim, Ji Yeon Song, Chang In Kim, Se Young Kim, Gwan Sun Lee
Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
Type:
Application
Filed:
July 23, 2009
Publication date:
August 18, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.
Type:
Application
Filed:
October 30, 2009
Publication date:
July 21, 2011
Applicant:
HANMI HOLDINGS CO., LTD.
Inventors:
Sang Min Yun, Dong Jin Hong, Weon Ki Yang, Jae Ho Yoo, Ji Sook Kim, Moon Sub Lee, Han Kyong Kim, Eun Jung Lim, Young Ho Moon, Young-Kil Chang, Gwan Sun Lee